

**January 30, 2025**

To  
The Corporate Relations Department  
**BSE Limited,**  
Phiroze Jeejeebhoy Towers,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai - 400001  
**Company Code No. 526301**

Dear Sir/Madam,

**Subject: Outcome of the Board Meeting held on January 30, 2025.**

We hereby inform you that, the Board of Directors at its meeting held today i.e. on **Thursday, January 30, 2025** has, inter-alia, considered and approved:

1. The Unaudited Standalone and Consolidated Financial Results of the Company for the third quarter and nine months ended December 31, 2024.

A signed copy of the above Financial Results along with Limited Review Report issued by the Statutory Auditors thereon under Regulation 33 of the Listing Regulations are enclosed to this letter.

2. Appointment of Ms. Muttana Venkata Ramana, as Internal Auditor of the Company with effect from January 30, 2025 for the FY 2024-25 and onwards.
3. Appointment of Mr. Satish Bollineni, as Chief Financial Officer (CFO) of the Company with effect from January 30, 2025.

The disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 and other applicable circulars, if any, for point no. 2 & 3 above are enclosed herewith as “**Annexure - A**”.

The Meeting commenced at 1:00 P.M. (IST) and concluded at 3:10 P.M. (IST).

Kindly take the same on record.

Thanking You.  
For **Medinova Diagnostic Services Limited**

**Hansraj Singh**  
**Company Secretary & Compliance Officer**  
**M.No.F11438**

Encl.: As above

**Annexure – A**

**DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Ms. Muttana Venkata Ramana (Internal Auditor)</b>	<b>Mr. Satish Bollineni (Chief Financial Officer)</b>
1.	Reasons for change viz. appointment, resignation, removal, death or otherwise.	Appointment	Appointment
2.	Date of Appointment & term of appointment	With effect from January 30, 2025, for the FY 2024-25 and onwards.	With effect from January 30, 2025.
3.	Brief Profile (in case of appointment)	Ms. Muttana Venkata Ramana is a Chartered Accountant with over 5 years of experience in Preparation of Financial Statements, Internal Audit and Related party transaction.	Mr. Satish Bollineni is a Chartered Accountant with over decade of experience in Financial Planning & Analysis, Financial Reporting, IND AS Implementation, Taxation, Treasury, Auditing, Mergers & Acquisitions and Investor Relations in diverse roles across the organisational hierarchy and working across Multinational companies/ Indian/ Public/ closely held companies in IT, Consulting, Pharma & Lifesciences and Healthcare domain.  He was previously associated with reputed organisations such as Infosys Limited, BSR & Associates (KPMG) and Sai Life Sciences Limited.
4.	Disclosure relationships between directors (in case of appointment of a director)	Not Applicable	Not Applicable

**M.ANANDAM & CO.,**  
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results  
of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure  
Requirements) Regulations, 2015**


**Review Report to the Board of Directors  
Medinova Diagnostic Services Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Medinova Diagnostic Services Limited (the "Company") for the quarter ended 31<sup>st</sup> December, 2024 and year to date results for the period 1<sup>st</sup> April, 2024 to 31<sup>st</sup> December, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited standalone financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. Anandam & Co.,  
Chartered Accountants  
(Firm Regn.No.000125S)

ABHIRAM  
VENKATA  
MAMIDIPUDI



Digitally signed by  
ABHIRAM VENKATA  
MAMIDIPUDI  
Date: 2025.01.30 15:07:09  
+05'30'

M. V. Abhiram  
Partner  
Membership Number: 266427  
UDIN: **25266427BMLFOG5981**

Place: Secunderabad  
Date: 30-01-2025

**MEDINOVA DIAGNOSTIC SERVICES LIMITED**  
CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

**STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2024**

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
<b>1</b>	<b>Income:</b>						
	(a) Revenue from Operations	174.58	197.70	182.32	557.79	586.52	778.12
	(b) Other Income	4.76	2.16	4.32	8.91	10.23	25.78
	<b>Total Income</b>	<b>179.34</b>	<b>199.86</b>	<b>186.64</b>	<b>566.70</b>	<b>596.75</b>	<b>803.90</b>
<b>2</b>	<b>Expenses</b>						
	(a) Cost of Materials Consumed	11.27	13.74	19.29	41.55	65.55	85.51
	(b) Employee Benefits Expense	40.65	41.96	41.98	124.27	133.16	173.34
	(c) Testing Fees	22.02	19.84	13.77	56.88	44.79	60.06
	(d) Finance Costs	12.60	12.60	14.49	37.67	43.32	57.40
	(e) Depreciation and amortisation expenses	3.71	3.59	3.17	10.45	9.17	12.30
	(f) Other Expenses	64.93	73.79	77.86	215.53	238.51	313.62
	<b>Total Expenses</b>	<b>155.18</b>	<b>165.52</b>	<b>170.56</b>	<b>486.35</b>	<b>534.50</b>	<b>702.23</b>
<b>3</b>	<b>Profit before Tax [1-2]</b>	<b>24.16</b>	<b>34.34</b>	<b>16.08</b>	<b>80.35</b>	<b>62.25</b>	<b>101.67</b>
<b>4</b>	<b>Tax Expense</b>						
	(a) Current Tax	3.32	8.91	3.31	14.32	10.81	20.39
	(b) Earlier Year's Tax	-	-	-	-	0.01	0.01
	(c) Deferred Tax	1.12	0.66	1.10	4.90	5.62	6.00
	<b>Total tax expense</b>	<b>4.44</b>	<b>9.57</b>	<b>4.41</b>	<b>19.22</b>	<b>16.44</b>	<b>26.40</b>
<b>5</b>	<b>Profit/Loss for the period (3-4)</b>	<b>19.72</b>	<b>24.77</b>	<b>11.67</b>	<b>61.13</b>	<b>45.81</b>	<b>75.27</b>
<b>6</b>	<b>Other Comprehensive Income</b>						
	Items that will not be reclassified to Profit or Loss :						
	i) Remeasurement of defined benefit plans	-	-	-	-	-	1.63
	ii) Income tax relating to above	-	-	-	-	-	(0.41)
<b>7</b>	<b>Total Comprehensive Income for the period (5+6)</b>	<b>19.72</b>	<b>24.77</b>	<b>11.67</b>	<b>61.13</b>	<b>45.81</b>	<b>76.49</b>
<b>8</b>	<b>Paid-up Equity Share capital (Face Value Rs 10/- per share)</b>	<b>995.68</b>	<b>995.68</b>	<b>995.68</b>	<b>995.68</b>	<b>995.68</b>	<b>995.68</b>
<b>9</b>	<b>Earnings per Equity Share (not annualised)</b>						
	a) Basic (Rs.)	<b>0.20</b>	<b>0.25</b>	<b>0.12</b>	<b>0.61</b>	<b>0.46</b>	<b>0.75</b>
	b) Diluted (Rs.)	<b>0.20</b>	<b>0.25</b>	<b>0.12</b>	<b>0.61</b>	<b>0.46</b>	<b>0.75</b>

**Notes**

1. The above Standalone financial results of Medinova Diagnostic Services Limited ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. The above standalone financial results were reviewed by the audit committee and approved by the Board of Directors in their respective meetings held on 30th January 2025. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended 31st December 2024. An unmodified report has been issued by them thereon.

3. The Company has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".

4. The Board of Directors of the Company at their meeting held on June 26, 2024, have considered and approved the proposed Scheme of Amalgamation of the Company ("Transferor Company") with and into the Holding Company, "Vijaya Diagnostic Centre Limited" (Transferee Company) with effect from April 01, 2024 ('the Appointed Date') under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and other rules and regulations framed thereunder ("Scheme"). The Company has received observation letter with "no adverse observations" from the BSE Limited and SEBI on December 05, 2024, and further the scheme is subject to the approval of Shareholders and Creditors of the respective companies and National Company Law Tribunal, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.

**For MEDINOVA DIAGNOSTIC SERVICES LIMITED**

SURA  
SURENDRANATH  
REDDY

Digitally signed by SURA  
SURENDRANATH REDDY  
Date: 2025.01.30 13:06:39  
+05'30'

**Dr. S. SURENDRANATH REDDY**  
**CHAIRMAN**  
**DIN 00108599**

**Place: Hyderabad**  
**Date: 30-01-2025**

**M.ANANDAM & CO.,**  
CHARTERED ACCOUNTANTS

**Independent Auditor's Review Report on the Quarterly Consolidated Unaudited Financial Results of  
the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure  
Requirements) Regulations, 2015**

**Review Report to the Board of Directors  
Medinova Diagnostic Services Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Medinova Diagnostic Services Limited ("the Holding Company") and its wholly owned subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended 31<sup>st</sup> December, 2024 and year to date results for the period 1<sup>st</sup> April, 2024 to 31<sup>st</sup> December, 2024 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. The Statement includes the results of the wholly owned subsidiary, Medinova Millenium MRI Services LLP.
  
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited consolidated financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M. Anandam & Co.,  
Chartered Accountants  
(Firm Regn.No.000125S)

ABHIRAM  
VENKATA  
MAMIDIPUDI

Digitally signed by  
ABHIRAM VENKATA  
MAMIDIPUDI  
Date: 2025.01.30 15:08:17  
+05'30'

M. V. Abhiram  
Partner  
Membership Number: 266427

UDIN: 25266427BMLFOH9593

Place: Secunderabad  
Date: 30-01-2025

**MEDINOVA DIAGNOSTIC SERVICES LIMITED**

CIN: L85110TG1993PLC015481

Regd. Office : H.No. 7-1-58, Unit No. 1/Flat No.301, 3rd Floor, Amrutha Business Complex, Ameerpet, Hyderabad - 500 016.

**STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31st DECEMBER, 2024**

(Rs. in Lakhs)

Sl. No.	Particulars	Quarter Ended			Nine Months Ended		Year Ended
		31.12.2024 (Unaudited)	30.09.2024 (Unaudited)	31.12.2023 (Unaudited)	31.12.2024 (Unaudited)	31.12.2023 (Unaudited)	31.03.2024 (Audited)
1	<b>Income:</b>						
	(a) Revenue from Operations	225.09	256.08	238.82	730.22	767.32	1,016.52
	(b) Other Income	2.89	2.55	3.08	7.11	6.67	19.82
	<b>Total Income</b>	<b>227.98</b>	<b>258.63</b>	<b>241.90</b>	<b>737.33</b>	<b>773.99</b>	<b>1,036.34</b>
2	<b>Expenses</b>						
	(a) Cost of Materials Consumed	14.16	17.66	22.83	52.36	76.92	100.29
	(b) Employee Benefits Expense	44.23	45.94	46.23	137.32	146.05	190.40
	(c) Testing Fees	22.02	19.84	11.62	56.88	37.66	49.86
	(d) Finance Costs	12.60	12.60	14.49	37.67	43.32	57.40
	(e) Depreciation	3.83	3.61	3.27	10.70	9.48	12.73
	(f) Other Expenses	79.23	92.60	98.37	268.66	302.95	397.77
	<b>Total Expenses</b>	<b>176.07</b>	<b>192.25</b>	<b>196.81</b>	<b>563.59</b>	<b>616.38</b>	<b>808.45</b>
3	<b>Profit before Tax</b>	<b>51.91</b>	<b>66.38</b>	<b>45.09</b>	<b>173.74</b>	<b>157.61</b>	<b>227.89</b>
4	<b>Tax Expense</b>						
	(a) Current Tax	12.24	15.67	3.31	37.36	10.81	20.39
	(b) Earlier Year's Tax	-	-	-	-	0.01	0.01
	(c) Deferred Tax	1.53	0.95	1.50	6.24	6.80	7.60
	<b>Total tax expense</b>	<b>13.77</b>	<b>16.62</b>	<b>4.81</b>	<b>43.60</b>	<b>17.62</b>	<b>28.00</b>
5	<b>Profit/Loss for the period (3-4)</b>	<b>38.14</b>	<b>49.76</b>	<b>40.28</b>	<b>130.14</b>	<b>139.99</b>	<b>199.89</b>
6	<b>Other Comprehensive Income</b>						
	Items that will not be reclassified to Profit or Loss :						
	i) Remeasurement of defined benefit plans	-	-	-	-	-	1.63
	ii) Income tax relating to above	-	-	-	-	-	(0.41)
7	<b>Total Comprehensive Income for the period (5+6)</b>	<b>38.14</b>	<b>49.76</b>	<b>40.28</b>	<b>130.14</b>	<b>139.99</b>	<b>201.11</b>
	<b>Net Profit attributable to:</b>						
	(a) Owners of the Company	38.14	49.76	40.28	130.14	139.99	199.89
	(b) Non Controlling Interest	-	-	-	-	-	-
	<b>Other Comprehensive Income attributable to:</b>						
	(a) Owners of the Company	-	-	-	-	-	1.22
	(b) Non Controlling Interest	-	-	-	-	-	-
	<b>Total Comprehensive Income attributable to:</b>						
	(a) Owners of the Company	38.14	49.76	40.28	130.14	139.99	201.11
	(b) Non Controlling Interest	-	-	-	-	-	-
8	<b>Paid-up Equity Share capital (Face Value Rs 10/- per share)</b>	<b>995.68</b>	<b>995.68</b>	<b>995.68</b>	<b>995.68</b>	<b>995.68</b>	<b>995.68</b>
9	<b>Earnings per Equity Share (not annualised)</b>						
	a) Basic (Rs.)	<b>0.38</b>	<b>0.50</b>	<b>0.40</b>	<b>1.31</b>	<b>1.40</b>	<b>2.00</b>
	b) Diluted (Rs.)	<b>0.38</b>	<b>0.50</b>	<b>0.40</b>	<b>1.31</b>	<b>1.40</b>	<b>2.00</b>

**Notes**

- The above Consolidated financial results of Medinova Diagnostic Services Limited ("the Company") have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 ('the Act') read with the relevant rules thereunder and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- The above consolidated financial results have been reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on 30th January, 2025. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended 31 December 2024. An unmodified report has been issued by them thereon.
- The above results include the results of the wholly owned subsidiary, Medinova Millennium MRI Services LLP
- The Group has one reportable segment (viz. Diagnostic Services) as per the requirements of Ind AS 108 "Operating Segments".
- The Group has prepared consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".
- The Board of Directors of the Company at their meeting held on June 26, 2024, have considered and approved the proposed Scheme of Amalgamation of the Company ("Transferor Company") with and into the Holding Company, "Vijaya Diagnostic Centre Limited" (Transferee Company) with effect from April 01, 2024 ('the Appointed Date') under Sections 230 to 232 and other applicable provisions of the Companies Act, 2013, and other rules and regulations framed thereunder ("Scheme"). The Company has received observation letter with "no adverse observations" from the BSE Limited and SEBI on December 05, 2024, and further the scheme is subject to the approval of Shareholders and Creditors of the respective companies and National Company Law Tribunal, and such other approvals, permissions, and sanctions of regulatory and other authorities as may be necessary.

**For MEDINOVA DIAGNOSTIC SERVICES LIMITED**

SURA SURENDRANATH  
REDDY

**DR. S. SURENDRANATH REDDY**

**CHAIRMAN**

**DIN 00108599**

**Place: Hyderabad**

**Date : 30-01-2025**

Digitally signed by SURA  
SURENDRANATH REDDY  
Date: 2025.01.30 13:05:00 +05'30'